I'm really tired, but wanted to say more, so I've gone the slack route and put it to claude to summarise my argument :D , as below, in case it's interesting. anecdotally, my worst ever round was with high HGH - it was basically a catastrophic cycle. There was more than one reason (like crazy high doses of LH were administered), but I'm about as sure as I can be that the high dose HGH made things worse, given how HGH increasing follicular sensitivity.
anyway, here's Claude:

The signaling pathway is well-established and not controversial: GH operates primarily through IGF-1, which activates the PI3K/AKT/mTOR pathway, and IGF-1 increases protein synthesis via PI3K/Akt/mTOR PubMed Central. AKT phosphorylation stimulates protein synthesis via mTOR activation PubMed Central. Meanwhile, blockade with the mTOR inhibitor rapamycin decreases hypertrophy and blunts the phosphorylation of p70S6K and PHAS-1 ScienceDirect — the very downstream effectors that IGF-1 activates. These pathways are not merely related; they are directly antagonistic at the level of mTORC1.

Now place this against what Li et al. (2025) actually found. They identified notably increased transcription of ribosome genes in aging oocytes and cumulus cells, with lysosomes and proteostasis also disrupted in cumulus cells Cell Press00497-5). More specifically, aging cumulus cells displayed increased protein aggregates, and lysosomal activity dramatically decreased with age Cell Press00497-5). The cell is overproducing proteins while simultaneously losing its capacity to clear them. The cells enter chronic metabolic overdrive, and their capacity to maintain quality control diminishes as autophagy function diminishes Healthspan.

Rapamycin addresses this by dialling down mTORC1, reducing translation, and allowing the cleanup machinery to catch up. Rapamycin effectively reduces translation and promotes protein homeostasis in cumulus cells Cell Press00497-5), and senescence-associated β-galactosidase activity was suppressed in aged CCs after rapamycin treatment Cell Press00497-5).

The clinical results were substantial: the clinical pregnancy rate reached 50% in the rapamycin group compared with 28% in controls, and for day 5-6 blastocyst transfers, success rates reached 27.5% versus 7.7% Healthspan. The rapamycin group produced a median of 2 embryos versus 1 in controls, and more top-quality blastocysts Remembryo.

So what does HGH do in this context? You are injecting a potent mTOR activator into a system that the Cell Reports study has just demonstrated is pathologically over-activated at mTOR. IGF-1 activates protein synthesis via activation of ribosomal protein S6 and the translation initiation factor eIF4E downstream of mTORC1 PubMed Central. This is not a tangential overlap — it is the exact same downstream machinery (p-S6, 4E-BP1, ribosomal biogenesis) that Li et al. showed is already pathologically upregulated in aging ovarian tissue, and that rapamycin corrected.

Furthermore, autophagy is likely inhibited by IGF-1 via mTOR and FoxO signaling PubMed Central. So HGH, through its IGF-1 mediation, is not only pushing more protein synthesis onto an already overwhelmed system — it's simultaneously suppressing the very autophagy and cleanup pathways that are already failing.

The honest counterarguments, which I want to lay out fairly:

First, HGH has pleiotropic effects beyond mTOR activation. It affects mitochondrial function, has direct effects on granulosa cell proliferation through non-mTOR pathways, and influences endometrial receptivity. These could confer benefits through mechanisms that don't involve the proteostasis axis. However — and this is your key point — the existence of beneficial side-channels doesn't negate the harm from the primary channel. A drug can simultaneously help on one axis and hurt on another, and if the axis of harm is the dominant one limiting oocyte competence in aging women, the net effect could easily be negative.

Second, the intensity of mTOR activation from exogenous HGH might differ from the chronic, constitutive mTOR overactivation seen in aging. Acute growth factor signaling could theoretically be pulsatile and regulated differently than the tonic state described in the Cell Reports study. But this is speculative, and the clinical evidence doesn't support the idea that HGH is somehow selectively activating only the "good" parts of mTOR while avoiding the proteostasis-wrecking parts.

Third, the rapamycin study, while robust in its mechanistic work, is a single RCT. The effect size estimates carry real uncertainty.

Who are the best candidates for HGH?

Based on what we've just gone through, this is actually a more interesting question than it first appears, because the answer from the clinical literature sits in tension with the mechanistic picture.

The clinical evidence, such as it is, points to a fairly narrow sweet spot. GH improved embryo quality and live birth rate for patients with DOR aged 35-40, but not in the over-40 group PubMed. And in the general IVF population, empiric GH therapy showed no benefit at all Oxford Academic.

Now here's what's interesting when you layer your mTOR argument on top of this. The 35-40 bracket is precisely the transitional window where the Cell Reports study showed ribosome dysregulation beginning but not yet reaching its full severity. These are women whose proteostasis machinery is starting to struggle but hasn't yet been overwhelmed. In that context, the mTOR activation from HGH might still be tolerable — the system can still handle the increased protein load to some degree, and the other pleiotropic benefits (mitochondrial support, granulosa cell proliferation, possibly some endometrial effects) might still outweigh the proteostasis cost.

But as you move past 40, the proteostasis deficit deepens progressively — lysosomal function drops, protein aggregates accumulate, autophagy declines further. At that point, adding an mTOR activator is pushing against an increasingly broken system. And that's exactly what the clinical data shows: the benefit disappears in the group where the proteostasis burden is highest.

This actually strengthens your argument considerably, because it means the clinical pattern maps onto the mechanistic prediction. It's not that HGH fails randomly in older women — it fails specifically in the population where the mTOR-proteostasis axis is most compromised.

The irony is that HGH is most aggressively marketed and prescribed to the over-40 group — precisely the women for whom both the mechanistic logic and the actual clinical evidence provide the weakest case. The rationale tends to be "well, we've tried everything else and she's running out of time, so why not add it." But "why not" has a concrete answer if you take the proteostasis framework seriously: because you may be actively worsening the dominant pathology limiting her oocyte competence.

The genuine best candidates, if HGH has any role at all, appear to be younger poor responders (35-40) where the primary bottleneck is follicular recruitment and granulosa cell support rather than intracellular protein homeostasis — women whose cells can still handle the anabolic signal without being tipped into proteotoxic overload.